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Background: The combination of inhaled corticosteroids and long-acting inhaled b2-
adrenergic-agonists has become the standard therapy for many patients with moderate to
severe persistent asthma. Whether the differences between budesonide/formoterol and
fluticasone/salmeterol translate into differences in treatment outcomes in a real life setting
is unknown.
Objectives: This study compared the use of healthcare services between new users of budeso-
nide/formoterol and fluticasone/salmeterol in a single inhaler between 2002 and 2004.
Methods: A 12-month population-based retrospective cohort study using administrative health
care databases was conducted. Asthma patients 16e65 years of age using budesonide/formo-
terol were matched according to age and markers of asthma severity to patients using flutica-
sone/salmeterol. The rate of emergency department (ED) visits for asthma, hospitalizations
for asthma, claims for oral corticosteroids, and visits to a respiratory specialist were compared
between the two groups using Poisson regression models. The mean number of doses of short-
acting b2-adrenergic-agonists (SABA) per week was compared between the two groups using
a linear regression model.
Results: Users of budesonide/formoterol were found to be less likely to have an ED visit for
asthma (adjusted RRZ 0.72; 95% CI: 0.54e0.96), a hospitalization for asthma (adjusted
RRZ 0.50; 95% CI: 0.25e0.99), a claim for oral corticosteroids (adjusted RRZ 0.83; 95%t exacerbation might be treated preferentially with budesonide/formoterol since users of these
ely to need acute care for asthma than users of fluticasone/salmeterol in the same inhaler.
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238 L. Blais et al.CI: 0.72e0.95), and use SABA (adjusted mean differenceZ  1.1 dose per week; 95% CI: 1.7;
0.5) than patients treated with fluticasone/salmeterol.
Conclusion: Our study has found that subjects initiating ICS/LABA treatment with budesonide/
formoterol had better outcomes than those initiating treatment with fluticasone/salmeterol.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Combination therapy with inhaled corticosteroids (ICS) and
long-acting inhaled b2-adrenergic-agonists (LABA) is rec-
ommended by the Canadian and International Asthma
Management Guidelines to treat adult persistent asthma
after suboptimal improvement with an ICS.1,2 However,
combination therapy is not recommended as a first-line
therapy in patients with mild to moderate persistent
asthma who have never used an ICS.3,4 In adults with
moderate to severe persistent asthma, combination
therapy is more beneficial than a higher dose of ICS with
respect to lung function, symptoms, and use of rescue
medication.5e7
Two products combining an ICS and a LABA in the same
inhaler are available in Canada. One product combines
budesonide and formoterol in a dry powder inhaler (DPI)
and the other product combines fluticasone propionate and
salmeterol in either a DPI or a pressurized metered dose
inhaler (pMDI). In addition to differences in the inhalation
devices, these two combination products have different
pharmacological properties; for example, the budesonide/
formoterol combination has been shown to have a faster
onset of action than the fluticasone propionate/salmeterol
combination with regards to improvements in FEV1, which is
attributable to the faster onset of formoterol over salme-
terol.8 Furthermore, fluticasone is about 25% more potent
than budesonide.9 Despite these different pharmacological
properties, the two combination products were found to
lead to similar benefits in terms of preventing the symp-
toms of asthma, use of rescue medications and lung func-
tion measures when they were compared at fixed dosing.10
Recently, however, a reduction in the rate of hospitaliza-
tion has been found with budesonide/formoterol combi-
nation compared to fluticasone propionate/salmeterol.11,12
It is unknown whether differences in pharmacologic
properties translate into differences in patient adherence
and consequently into clinical differences. In order to
answer these questions, we undertook a population-based
retrospective cohort study to compare the rate of use of
acute care and ambulatory visits for asthma and treatment
adherence between new users of budesonide/formoterol
and new users of fluticasone propionate/salmeterol in
a single inhaler.
Methods
Source of data
This study was based on the administrative health care
databases of the Re´gie de l’assurance-maladie du Que´bec
(RAMQ), the government body responsible for themanagement of health care services. In the Canadian
province of Que´bec, the public drug insurance plan is
managed by the RAMQ and covers approximately 43% of
the population, including residents receiving social assis-
tance, the elderly, and residents less than 65 years of age
who have no access to a private drug insurance plan
through their employer. From the RAMQ’s Prescription
Database, we obtained data on medication claims such as
the date the medication was dispensed, name, dose,
quantity, and dosage form of the prescribed medication,
duration of the prescription, and the specialty of the
prescribing physician. From the RAMQ’s Medical Services
Database, we obtained data on the dispensed medical
services, such as the date and site of service (clinic,
emergency department (ED) or hospital), the diagnosis
coded with ICD-9, and the specialty of the treating
physician. From the RAMQ, we also obtained socio-demo-
graphic data such as age, gender, type of drug insurance
plan, area of residence, and where relevant, date of
death. All these databases contain a patient unique
identifier number that allows for the linkage between
them.
Study design
We used a retrospective matched cohort in which each
patient was followed for 12 months. Using the RAMQ’s
databases, we first selected a cohort of patients newly
treated with either budesonide/formoterol or fluticasone
propionate/salmeterol. Patients were included in the cohort
if they fulfilled the following inclusion/exclusion criteria: (1)
at least one claim for a combination therapy in 2002 or 2003;
(2) no evidence of a claim for combination therapy for at
least 1 year prior to the first claim (the date of the first claim
of a combination therapy is referred to as the index date); (3)
age between 16 and 65 years on the index date; (4) having
had at least one diagnosis for asthma in the year prior to the
index date (ICD-9: 493.0, 493.1, 493.9); (5) having had no
diagnosis or claim for a respiratory disease other than
asthma in the year prior to the index date; and (6) being
covered by the RAMQ’s Public Drug Insurance Plan for at least
1 year prior and 1 year after the index date.
Patients treated with budesonide/formoterol were then
one-to-one matched to patients treated with fluticasone
propionate/salmeterol based upon the following criteria:
age (25, >25e35, >35e45, >45e55, and >55e65 years
old), gender, calendar year of the index date, as well as use
of inhaled corticosteroids (0, 1 claim), oral corticoste-
roids (0, 1, 2, 3 claims), ED visits for asthma (0, 1, 2
visits), and hospitalization for asthma (0, 1 hospitaliza-
tion) in the year prior to the index date. Patients entered
the cohort on the index date and were followed-up for
12 months.
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Patients newly treated with budesonide/formoterol were
compared to patients newly treated with fluticasone
propionate/salmeterol in a real life setting.
Outcomes
The following outcomes were investigated: ED visits for
asthma (ICD-9: 493.0, 493.1, 493.9), hospitalizations for
asthma (ICD-9: 493.0, 493.1, 493.9), claims for oral corti-
costeroids, doses of short-acting inhaled b2-agonists (SABA)
per week, visits to a respiratory specialist (ICD-9: 493.0,
493.1, 493.9), ambulatory medical visits (any diagnosis),
and treatment adherence to a combination therapy.
To obtain an estimate of SABA use, we developed an
algorithm to obtain equivalencies between the different
medications dispensed using the medication’s dose,
formulation, date of claims, prescription renewals as well
as the period between renewals.13 Treatment adherence
was defined as the number of claims of the combination
therapy in the year following the index date.
Confounding variables
In order to further adjust for differences between patients
treated with budesonide/formoterol and fluticasone
propionate/salmeterol, we considered the following vari-
ables as potential confounders: area of residence on the
index date (rural/urban), receipt of social assistance on the
index date (yes/no), dose of ICS prescribed on the index
date (500, >500 mg per day in fluticasone propionate
equivalent according to the equivalences reported in the
Canadian Asthma Consensus Guidelines1), combination
therapy initiated by a respiratory physician (yes/no) as well
as the number of doses of SABA per week (3, 4 doses),
use of LABA (yes/no), and visits to a respiratory physician in
the year prior to the index date.
Statistical analyses
Users of budesonide/formoterol were first compared to
users of fluticasone propionate/salmeterol with respect to
the socio-demographic characteristics of the patients at
cohort entry and asthma related variables using descriptive
statistics. We then compared the crude proportions of
patients with an ED visit for asthma, a hospitalization for
asthma, a claim for oral corticosteroids, and a visit to
a respiratory specialist between users of budesonide/for-
moterol and fluticasone propionate/salmeterol using the
Chi-squared tests. In addition, the mean number of doses of
SABA per week and the mean number of ambulatory
medical visits in the 12-month follow-up period were
compared between budesonide/formoterol and fluticasone
propionate/salmeterol users with t-tests.
In order to take into account the aforementioned
potential confounders, the association between all study
outcomes except the use of SABA and the type of combina-
tion therapy were analyzed using the Poisson regression
models. One model including all confounding variables was
first built for each outcome. A backward selection strategywas then used to find the reduced model for each outcome
separately.14 Crude and adjusted rate ratios were estimated
and 95% confidence intervals (CI) were reported for adjusted
rate ratios. A linear regression model was used to estimate
the crude and adjusted mean differences in the number of
doses of SABA per week between budesonide/formoterol
and fluticasone propionate/salmeterol. A backward selec-
tion strategy was also used to find the reduced model. 95%
CIs were reported for adjusted mean differences.
For patients’ adherence, we used a t-test to compare
the mean number of claims in the year following the index
date between users of budesonide/formoterol and users of
fluticasone propionate/salmeterol.Results
We initially identified 1449 asthma patients newly treated
with budesonide/formoterol and 9381 asthma patients
newly treated with fluticasone/salmeterol from the RAMQ
databases. After matching, 1264 patients (87.2%) using
budesonide/formoterol and 1264 patients (13.5%) using
fluticasone/salmeterol were kept in the study matched
cohort. In Table 1, we present the characteristics of the
study patients: patients were 43 years old on average, 66%
were female while a minority of them lived in a rural area
and received social assistance. Patients treated with
budesonide/formoterol were less likely to receive higher
doses of ICS when the combination therapy was started, but
more likely to have their combination therapy prescribed
by a respiratory specialist than patients treated with fluti-
casone propionate/salmeterol. Moreover, a larger propor-
tion of the budesonide/formoterol patients had
leukotriene-receptor antagonists and a visit with a respira-
tory specialist in the year prior to the combination therapy.
In Table 2, we compared the crude proportions of patients
with the study outcomes in the year following the index date,
between the budesonide/formoterol and fluticasone propi-
onate/salmeterol groups. Patients treated with budesonide/
formoterol were significantly less likely to have an ED visit for
asthma and to use high doses of SABA, but weremore likely to
have a visit with a respiratory physician than patients treated
with fluticasone propionate/salmeterol. Overall, there were
80 ED visits for asthma, 12 hospitalizations for asthma, and
764 visits to a respiratory specialist in the year following the
initiation of the budesonide/formoterol therapy. Corre-
sponding figures were 111, 26 and 571 in the fluticasone
proprionate/salmeterol group.
In Table 3, we present the results of the regression
analyses that provided the adjusted measures of associa-
tions between the type of combination therapy and the
outcomes under study. These analyses revealed that after
adjustment for confounding variables, patients treated
with budesonide/formoterol were significantly less likely to
have an ED visit for asthma (adjusted rate ratio
(RR)Z 0.72; 95% CI: 0.54e0.96), a hospitalization for
asthma (adjusted RRZ 0.50; 95% CI: 0.25e0.99), a claim
for oral corticosteroids (adjusted RRZ 0.83; 95% CI: 0.72e
0.95), and to use SABA (adjusted mean differenceZ  1.1
dose per week; 95% CI: 1.7; 0.5) than patients treated
with fluticasone propionate/salmeterol in the year
following the initiation of the combination therapy. On the
Table 1 Patient’s characteristics.
BUD/FM DPI FP/SM DPI/pMDI
Number of patients 1264 1264
Socio-demographics
Age on the index date*, mean  SD 43.4  14.3 43.4  14.2
n (%) n (%)
Female gender* 839 (66.4) 839 (66.4)
Living in a rural area 267 (21.1) 245 (19.4)
Receipt of social assistance 391 (30.9) 478 (37.8)
At initiation of the combination therapy
Daily dose of inhaled corticosteroids prescribed
(mg in fluticasone proprionate equivalent)
500 868 (68.7) 725 (57.4)
>500 396 (31.3) 539 (42.6)
Mean  SD 543  243 706  654
Prescription made by a respiratory physician 286 (22.6) 139 (11.0)
In the year prior to the initiation of the combination therapy
Daily dose of inhaled corticosteroids*
(mg in fluticasone proprionate equivalent)
0 547 (43.3) 547 (43.3)
>0e250 536 (42.4) 536 (42.4)
>250e500 127 (10.0) 127 (10.0)
>500 54 (4.3) 54 (4.3)
Mean  SD 378  330 467  450
Number of claims of oral corticosteroids*
0 1066 (84.3) 1066 (84.3)
1 135 (10.7) 135 (10.7)
2 or more 63 (5.0) 63 (5.0)
Number of doses per week of SABA
3 667 (52.8) 679 (53.7)
4 597 (47.2) 585 (46.3)
1 claim for a LABA 333 (26.3) 123 (9.7)
1 claim for a leukotriene-receptor antagonist 126 (10.0) 73 (5.8)
1 claim for a theophylline 26 (2.1) 29 (2.3)
1 ED visit for asthma* 85 (6.7) 85 (6.7)
1 hospitalization for asthma* 7 (0.6) 7 (0.6)
1 visit to a respiratory physician 315 (24.9) 169 (13.4)
1 claim for an intranasal corticosteroids or a diagnosis of rhinitis 297 (23.5) 253 (20.0)
BUD/FM DPI: budesonide and formoterol in a dry powder inhaler. FP/SM DPI/pMDI: fluticasone proprionate and salmeterol in either a dry
powder inhaler or a pressurized metered dose inhaler. *Matching variables.
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the two groups for the rate of ambulatory medical visits and
visits to a respiratory physician.
In terms of treatment adherence, we found that patients
treated with budesonide/formoterol and fluticasone
propionate/salmeterol had 4.2 and 3.9 prescriptions on
average in the year following the initiation of the combi-
nation therapy, respectively (p-valueZ 0.0703). The
average daily dose of ICS during the study follow-up was
388 mg in fluticasone propionate equivalent for budesonide/
formoterol and 359 mg for fluticasone/salmeterol.
Discussion
In our study, users of budesonide/formoterol in a single
inhaler were less likely than users of fluticasone/salmeterolin a single inhaler to have an ED visit or a hospitalization for
asthma, and they also had fewer claims for oral cortico-
steroids and SABA.
Two clinical studies have compared the efficacy of
budesonide/formoterol and fluticasone/salmeterol in fixed
dosing regimens and found similar reductions in asthma
exacerbations and asthma control between groups.10,15 In
the study by Aalbers et al., 658 adults with moderate to
severe asthma were randomized to budesonide/formoterol
DPI 200/6 mg, two inhalations twice daily, or fluticasone/
salmeterol DPI 250/50 mg, one inhalation twice daily, and
improvements in ‘‘well-controlled asthma week’’ were
similar in both groups in the first month of fixed dosing.15
The following 6 months of the study compared adjustable
maintenance dosing of budesonide/formoterol to fixed
dosing of fluticasone/salmeterol. Therefore, the time
Table 2 Crude distribution of outcomes in the year following the initiation of the combination therapy comparing patients
treated with budesonide/formoterol and fluticasone proprionate/salmeterol.
BUD/FM DPI FP/SM DPI/pMDI p-value
Number of patients nZ 1264 nZ 1264
1 ED visit for asthma, n (%) 59 (4.7) 84 (6.6) 0.031
1 hospitalization for asthma, n (%) 11 (0.9) 16 (1.3) 0.333
Number of claims of oral corticosteroids, n (%)
0 1037 (82.0) 1025 (81.1) 0.632
1 133 (10.5) 148 (11.7)
2 or more 94 (7.4) 91 (7.2)
1 visit to a respiratory physician, n (%) 316 (25.0) 214 (16.9) <0.001
Number of ambulatory medical visits, mean  SD 7.5  7.4 7.3  7.0 0.523
Doses of SABA per week, mean  SD 5.3  8.8 6.2  8.2 0.009
BUD/FM DPI: budesonide and formoterol in a dry powder inhaler. FP/SM DPI/pMDI: fluticasone proprionate and salmeterol in either a dry
powder inhaler or a pressurized metered dose inhaler.
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between both medications. In the study by Dahl et al., 1397
adults with moderate to severe asthma were randomized to
receive fluticasone/salmeterol DPI 250/50 mg, one inhala-
tion twice daily, or budesonide/formoterol DPI 200/6 mg,
two inhalations twice daily, and the overall rate of asthma
exacerbations (based on peak flow measurements, oral
corticosteroids use and hospital admission) was similar
between the groups after 6 months of follow-up.10 More
recently, Kuna et al. has found that treatment with fixed
dosing of budesonide/formoterol 200/6 mg, compared with
fluticasone/salmeterol 125/25 mg, two inhalations twice
daily, significantly reduced the rate of the most severe
asthma exacerbations requiring hospitalization or EDTable 3 Adjusted measures of association between the type of
BUD/FM DPI versus FP/
Crude rate ratio
ED visit for asthma 0.72
Hospitalizations for asthma 0.46
Claims for oral corticosteroids 0.96
Visits to a respiratory specialist 1.34
Ambulatory medical visits 1.02
Crude mean difference
Doses of SABA per week 0.9
BUD/FM DPI: budesonide and formoterol in a dry powder inhaler. FP/SM
powder inhaler or a pressurized metered dose inhaler.
a Rate ratio adjusted for: receipt of social assistance, use of SABA a
date.
b Rate ratio adjusted for: receipt of social assistance.
c Rate ratio adjusted for: dose of ICS prescribed on the index date, c
use of SABA, LABA, leukotriene-receptor antagonists, and theophylline
date.
d Rate ratio adjusted for: area of residence, dose of ICS prescribed
a respiratory specialist, use of SABA, and leukotriene-receptor antag
index date.
e Rate ratio adjusted for: area of residence, receipt of social assistan
initially prescribed by a respiratory specialist, use of SABA, LABA,
specialist in the year prior to the index date.
f Mean difference adjusted for: receipt of social assistance, use oftreatment.11 Furthermore, a meta-analysis combining the
results of these three clinical trials10,11,15 showed an overall
reduction in the rate of hospitalization for asthma exacer-
bation,12 which is in accordance with our study results.
Reasons explaining our study results remain unclear. It
is unlikely that our study results are explained by differ-
ences in the clinical efficacy of budesonide and flutica-
sone. Even though fluticasone and budesonide have
different pharmacological properties, both agents led to
similar reductions in asthma exacerbations in studies using
equipotent dosage in adults with chronic asthma.16 For-
moterol and salmeterol clearly have distinct pharmaco-
logical characteristics, but in clinical studies, both agents
led to similar improvements in FEV1,
17 morning PEF,18e21combination therapy and the outcomes under study.
SM DPI/pMDI
Adjusted rate ratio 95% CI
0.72a 0.54e0.96
0.50b 0.25e0.99
0.83c 0.72e0.95
0.97d 0.87e1.09
1.01e 0.98e1.04
Adjusted mean difference 95% CI
1.1f 1.7 to 0.5
DPI/pMDI: fluticasone proprionate and salmeterol in either a dry
nd leukotriene-receptor antagonists in the year prior to the index
ombination therapy initially prescribed by a respiratory specialist,
s and visit to a respiratory specialist in the year prior to the index
on the index date, combination therapy initially prescribed by
onists and visit to a respiratory specialist in the year prior to the
ce, dose of ICS prescribed on the index date, combination therapy
and leukotriene-receptor antagonists, and visit to a respiratory
SABA and LABA in the year prior to the index date.
242 L. Blais et al.rescue medication use,19 and asthma symptoms, in
patients who were receiving stable dose of various inhaled
corticosteroids.19e21
A few characteristics differed between the groups of
subjects compared to cohort entry. Subjects on budeso-
nide/formoterol were more likely to visit a respiratory
specialist and to have a claim for a LABA or a leukotriene-
receptor antagonist prior to cohort entry. These patients’
characteristics are likely associated with more severe or
less controlled asthma, but these differences would influ-
ence the results towards greater benefits in the flutica-
sone/salmeterol group, which was not found. When looking
at adherence to treatment, there were more refills in the
budesonide/formoterol group (4.2) than in the fluticasone/
salmeterol group (3.9), but the difference was small and
not statistically significant (0.3 inhaler over a 12 month
period).
Our study has some limitations. The subjects were not
randomized to one of the two study groups, but users of
budesonide/formoterol were matched to users of flutica-
sone/salmeterol according to characteristics that could
have influenced the study outcomes. Furthermore, the
regression analyses were done to account for potential
confounding variables. The use of asthma medications is
measured with filled prescriptions and this might not
reflect the exact use of the medication. This is especially
true for SABA since patients might have some reserve of
this rescue medication, but this phenomenon should not
differ between the compared groups. Asthma diagnosis
was not necessarily confirmed by spirometry in all cases.
However, asthma diagnosis was physician based and we
used validated codes to confirm them.22 Finally, our cohort
under represents patients with high socio-economic status
who have private drug insurance. However, there is no
reason to believe that the socio-economic status of
patients would act as an effect modifier for the associa-
tions under study.
In conclusion, our study shows more benefits of for-
moterol/budesonide over salmeterol/fluticasone in real
clinical practice. Further studies are needed to confirm
these findings and to identify reasons that could explain the
observed differences in clinical effectiveness between
these two combination products. Moreover, we need to
understand the reasons behind the low rate of prescription
renewals in order to be able to intervene efficaciously an
improve drug therapy in asthma patients.Conflict of interest statement
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